130 related articles for article (PubMed ID: 20660294)
1. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
Karsdal MA; Henriksen K; Bay-Jensen AC; Molloy B; Arnold M; John MR; Byrjalsen I; Azria M; Riis BJ; Qvist P; Christiansen C
J Clin Pharmacol; 2011 Apr; 51(4):460-71. PubMed ID: 20660294
[TBL] [Abstract][Full Text] [Related]
2. Oral salmon calcitonin--pharmacology in osteoporosis.
Henriksen K; Bay-Jensen AC; Christiansen C; Karsdal MA
Expert Opin Biol Ther; 2010 Nov; 10(11):1617-29. PubMed ID: 20932224
[TBL] [Abstract][Full Text] [Related]
3. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
[TBL] [Abstract][Full Text] [Related]
4. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Lau EM; Arnold M; Christiansen C
Osteoarthritis Cartilage; 2010 Feb; 18(2):150-9. PubMed ID: 19747581
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Dec; 8():12. PubMed ID: 19055791
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Christiansen C
J Clin Pharmacol; 2009 Feb; 49(2):229-34. PubMed ID: 19179298
[TBL] [Abstract][Full Text] [Related]
8. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
9. Influence of food intake on the bioavailability and efficacy of oral calcitonin.
Karsdal MA; Byrjalsen I; Azria M; Arnold M; Choi L; Riis BJ; Christiansen C
Br J Clin Pharmacol; 2009 Apr; 67(4):413-20. PubMed ID: 19371314
[TBL] [Abstract][Full Text] [Related]
10. Oral calcitonin.
Hamdy RC; Daley DN
Int J Womens Health; 2012; 4():471-9. PubMed ID: 23071417
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from the clinical development of oral peptides.
Karsdal MA; Riis BJ; Mehta N; Stern W; Arbit E; Christiansen C; Henriksen K
Br J Clin Pharmacol; 2015 May; 79(5):720-32. PubMed ID: 25408230
[TBL] [Abstract][Full Text] [Related]
12. Oral calcitonin.
Maricic MJ
Curr Osteoporos Rep; 2012 Mar; 10(1):80-5. PubMed ID: 22281725
[TBL] [Abstract][Full Text] [Related]
13. [Translational research on calcitonin].
Yamauchi H; Takahashi N
Nihon Rinsho; 2005 Oct; 63 Suppl 10():233-7. PubMed ID: 16279638
[No Abstract] [Full Text] [Related]
14. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
[TBL] [Abstract][Full Text] [Related]
15. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Christiansen C
Eur J Clin Pharmacol; 2010 Jan; 66(1):29-37. PubMed ID: 19813008
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality.
Karsdal MA; Henriksen K; Arnold M; Christiansen C
BioDrugs; 2008; 22(3):137-44. PubMed ID: 18481897
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective.
Hoyer H; Perera G; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2010 Jan; 36(1):31-44. PubMed ID: 19640245
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
19. Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.
Aguirre TAS; Aversa V; Rosa M; Guterres SS; Pohlmann AR; Coulter I; Brayden DJ
J Control Release; 2016 Sep; 238():242-252. PubMed ID: 27480451
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
